[1]余久如a,卢锦莲b,廖建红a,等.高效液相色谱法检测慢性肾功能不全患者羟苯磺酸钙稳态血药浓度与eGFR及肌酐干扰值相关性分析[J].现代检验医学杂志,2019,34(04):62-66.[doi:10.3969/j.issn.1671-7414.2019.04.015]
　YU Jiu-rua,LU Jin-lianb,LIAO Jian-honga,et al.Determination of the Steady-State Plasma Concentration of Calcium Dobesilate in Patients with Chronic Renal Insufficiency by HPLC and Its Correlation with eGFR and Creatinine Interference[J].Journal of Modern Laboratory Medicine,2019,34(04):62-66.[doi:10.3969/j.issn.1671-7414.2019.04.015]
点击复制

高效液相色谱法检测慢性肾功能不全患者羟苯磺酸钙稳态血药浓度与eGFR及肌酐干扰值相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年04期
页码:
62-66
栏目:
论著
出版日期:
2019-08-20

文章信息/Info

Title:
Determination of the Steady-State Plasma Concentration of Calcium Dobesilate in Patients with Chronic Renal Insufficiency by HPLC and Its Correlation with eGFR and Creatinine Interference
文章编号:
1671-7414(2019)04-062-05
作者:
余久如1a; 2; 卢锦莲1b; 廖建红1a; 2; 蔡维望1a; 2
(1.黄石市第二医院 a.检验科; b.肾病内科,湖北黄石 435002; 2.黄石医养医学检验实验室,湖北黄石 435004)
Author(s):
YU Jiu-ru1a; 2; LU Jin-lian1b; LIAO Jian-hong1a; 2; CAI Wei-wang1a; 2
(1a.Department of Laboratory Medicine; 1b.Department ofVephropathy Internal, the Second Hospital of Huangshi,Hubei Huangshi 435002,China; 2.Huangshi Laboratory of Medical and Nursing Laboratory,Hubei Huangshi 435004,China)
关键词:
肾功能不全;  羟苯磺酸钙;  高效液相色谱法;  稳态血药浓度
分类号:
R692; Q503
DOI:
10.3969/j.issn.1671-7414.2019.04.015
文献标志码:
A
摘要:
目的 采用高效液相色谱法(HPLC)检测患者羟苯磺酸钙常规剂量用药后的稳态血药浓度,分析该浓度与患者肾小球滤过率(eGFR)及药物所致肌酐干扰的相关性,为肾功能不全患者调整羟苯磺酸钙用药剂量提供依据。方法 ①选择并优化检测血清羟苯磺酸钙浓度的HPLC方法,并进行方法学评价; ②选择2016年5～10月间黄石市第二医院收治20例肾功能不全和10例非肾功能不全羟苯磺酸钙(剂量为1.5 g/d,Tid)用药患者,采集羟苯磺酸钙服药5天后清晨空腹静脉血,HPLC法检测血清羟苯磺酸钙浓度; ③比较肾功能不全组、非肾功能不全组稳态血清羟苯磺酸钙浓度差异,分析肾功能不全组稳态血清羟苯磺酸钙浓度与eGFR及肌氨酸氧化酶法肌酐干扰值相关性。结果 ①HPLC方法学评价结果:方法专属性色谱图表明羟苯磺酸钙、对氨基苯甲酸内标保留时间分别为:6.9和8.0 min,血清内源性物质不干扰羟苯磺酸钙测定; 羟苯磺酸钙及对氨基苯甲酸内标平均萃取回收率分别为:75.5%和94.5%,线性范围:1.90～189.60 mg/L(r2=0.999 1,P<0.01),检测低限:0.452 mg/L,平均加标回收率98.9%(95.6%～103.6%),18.96,94.80和189.60 mg/L三种浓度测试样品日内CV分别为4.8%,4.5%和4.1%,日间CV分别为6.3%,6.1%和5.4%。②稳态血清羟苯磺酸钙检测结果:肾功能不全组高于非肾功能不全组(146.10±91.86 vs 16.81±2.48 mg/L),差异有统计学意义(Z=-4.400,P<0.05)。③肾功能不全组稳态血清羟苯磺酸钙浓度与eGFR呈负相关(r=-0.790,P=0.000),回归方程为Y=6 080.61X-1.692(r2 =0.975 3,F=710.882,P=0.001); 肾功能不全组肌氨酸氧化酶法肌酐干扰值与稳态血清羟苯磺酸钙浓度呈正相关(r=0.816,P=0.000),回归方程为Y= 0.002 7X 2+0.343 5X+22.935(r2=0.987 5,F=671.064,P=0.000)。结论 肾功能不全患者常规剂量服用羟苯磺酸钙后出现与eGFR呈负相关的药物蓄积,建议肾功能不全患者使用羟苯磺酸钙应依据eGFR降低用药剂量。
Abstract:
Objective The steady-state plasma concentration of calcium dobesilate was measured by HPLC and its correlation with eGFR and drug-induced creatinine interference was analyzed, and provide the basis for adjusting the dosage of calcium dobesilate in patients with renal insufficiency.Methods ①Selected and optimized an HPLC method for detercting the concentration of calcium dobesilate in serum,and corried out methodological evaluation.②Selected 20 cases of renal insufficiency and 10 cases of non-renal insufficiency patients in the treatment of calcium dobesilate patients(in the dose of 1.5 g/d,Tid)from May to October of 2016.Collected fasting venous blood in the morning after inhalation of calcium dobesilate for 5 days,andthe concentration of calcium dobesilate in serum was detected by HPLC.③Compared the difference of stable serum calcium dobesilate concentration between renalinsufficiency group and non-renal insufficiency group,analysis of correlationof serum calcium dobesilate concentration and eGFR and creatine oxidase-induced creatinine interference in patients with functional insufficiency.Results ①Optimized HPLC methodological evaluation results:the retention time of calcium dobesilate and aminobenzoic acid were about 6.9 min and 8.0 min,respectively.The results showed that the serum endogenous substances did not interfere with the effect of calcium dobesilate.The recoveries of calcium dobesilate and internal standard p-aminobenzoic acid were 75.5% and 94.5%,respectively.The linear range was 1.90～189.60 mg/L(r2=0.999 1,P<0.05),and detection limit:0.452 mg/L.The average recoveries were 98.9%(95.6%～103.6%),and the CVs of three concentrations of test samples of 18.96,94.80 and 189.60 mg/L were 4.8%,4.5% and 4.1% respectively,and daytimeCV were:6.3%,6.1% and 5.4% respectively.②Steady-state serum calciumdobesilate test results:calcium dobesilate has a significant difference betweenthe two groups 14.61±91.86 vs 16.81±2.48 mg/L,the difference was statistically significant(Z=-4.400,P<0.05).③Serum calcium dobesilate concentration in patients with renal insufficiency was significantly negatively correlated with eGFR(r=-0.790,P=0.000).The regression equation was Y=608 0.61X-1.692(r2=0.975 3,F=710.882,P=0.001).The concentration ofcreatinine was significant positive correlation of steady-state serum calcium dobesilate(r=0.816,P=0.000).The regression equation was Y=0.002 7X2+0.343 5X+22.935(r2=0.987 5,F=671.064,P=0.000).Conclusion Patients with renal insufficiency had a negative association witheGFR after routine doses of calcium dobesilate.It is recommended that patientswith renal insufficiency use calcium dobesilate should be reduced according toeGFR.

参考文献/References:

[1] 刘晓城,吕永蔓,金晓冰,等.羟苯磺酸钙治疗慢性肾功能不全的临床观察[J].中华医学杂志,2004,84(22):1892-1893. LIU Xiaocheng,LU Yongman,JIN Xiaobing,et al.Clinical observationof calcium dobesilate in the treatment of chronic renal insufficiency[J].Natl Med J China,2004,84(22):1892-1893. [2] 袁文生,吴丰学,代凌云.羟苯磺酸钙治疗慢性肾功能不全药效研究[J].中外医学研究,2012,10(14):4-6. YUAN Wensheng,WU Fengxue,DAI Lingyun.The efficacy of calcium dobesilate in the treatment of chronic renal insuficiency[J].Chinese and ForeignMedical Researc,2012,10(14):4-6. [3] 余久如,潘桂红,鞠萍.羟苯磺酸钙对肌氨酸氧化酶法检测肌酐的干扰[J].中华检验医学杂志,2013,36(2):161-164. YU Jiuru,PAN Guihong,JU Ping.The effect of calcium dobesilate oncreatinine measurement by sarcosine oxidase assay[J].Chin J Lab Med,2013,36(2):161-164. [4] 郭栋,谭志荣,陈尧,等.高效液相色谱法测定人血浆中羟苯磺酸钙的浓度[J].药物分析杂志,2008,28(8):1252-1255. GUO Dong,TAN Zhirong,CHEN Yao,et al.HPLC determination of calcium dobesilate in human plasma[J].Chin J Pharm Anal,2008,28(8):1252-1255. [5] 夏素霞,唐思,王月敏,等.羟苯磺酸钙颗粒剂在健康人体的药代动力学和生物等效性[J].中国临床药理学杂志,2008,24(6):505-508. XIA Suxia,TANG Si,WANG Yuemin,et al.Pharmacokinetics and bioequivalence of calcium dobesilate granules in healthy volunteers[J].Chin J Clin Pharmacol,2008,24(6):505-508. [6] 张旖旎,陈笑艳,杨洪梅,等.反相离子对高效液相色谱法测定人血浆中羟苯磺酸[J].药物分析杂志,2007,27(8):1208-1211. ZHANG Yini,CHEN Xiaoyan,YANG Hongmei,et al.RP-HPLC determination of dobesilic acid in human plasma[J].Chin J Pharm Anal,2007,27(8):1208-1211. [7] WANG Xiangjun J,JIN Yinxiu,YING Jingyan,et al.Determination of rutindeca(H-)sulfate sodium in rat plasma using ion-pairing liquid chromatography after ion-pairing solid-phase extraction[J].Journalof Chromatography B,2006,833(2):231-235. [8] 吴炯,王冲,郭玮,等.肾小球滤过率的估算及其临床应用[J].中华检验医学杂志,2007,30(11):1214-1218. WU Jiong,WANG Chong,GUO Wei,et al.Assessment of the estimationsof glomerular filtration rate in Chinese diabetic patients[J].Chin J Lab Med,2007,30(11):1214-1218. [9] 刘运双,张彬,张亚梅,等.健康人群和慢性肾病患者基于血清CysC水平估算肾小球滤过率公式的适用性评价[J].现代检验医学杂志,2018,33(3):54-59,64. LIU Yunshuang,ZHANG Bin,ZHANG Yamei,et al.Evaluating of the applicability of estimated glomerular filtration rate formula based on cystatin C inhealthy population and chronic kidney disease patients[J].J Mod Lab Med,2018,33(3):54-59,64. [10] 国秀芝,张江涛,侯立安,等.羟苯磺酸钙对尿酸酶-过氧化物酶偶联法尿酸检测的干扰研究[J].中华检验医学杂志,2015,38(9):600-604. GUO Xiuzhi,ZHANG Jiangtao,HOU Li'an,et al.Negative interference by calcium dobesilate in uricase-peroxidase coupled assays of serum uric acid[J].Chin J Lab Med,2015,38(9):600-604.

相似文献/References:

[1]李岗峰,李刘文,刘　璐.慢性心力衰竭患者血清内源性Apela，NT-proBNP及CysC水平与并发肾功能不全的相关性分析[J].现代检验医学杂志,2022,37(03):167.[doi:10.3969/j.issn.1671-7414.2022.03.035]
　LI Gang-feng,LI Liu-wen,LIU Lu.Correlation Analysis of Serum Endogenous Apela, NT-proBNP, Cys C Levels and Renal Insufficiency in Patients with Chronic Heart Failure[J].Journal of Modern Laboratory Medicine,2022,37(04):167.[doi:10.3969/j.issn.1671-7414.2022.03.035]

备注/Memo

备注/Memo:
作者简介:余久如(1968-),男,本科,主任技师,研究方向:生化检验及分子生物学,E-mail:pangh0909@sina.com。 通讯作者:蔡维望(1986-),男,主管技师,硕士,E-mail:493584515@qq.com。收稿日期:2018-05-03 修回日期:2019-05-26
更新日期/Last Update: 2019-07-30